Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HIV-1 testing during labor

This article was originally published in The Gray Sheet

Executive Summary

Widespread rapid HIV testing during labor would be cost-saving to the medical system, according to authors of the CDC-funded, 91,707-patient, Mother-Infant Rapid Intervention At Delivery (MIRIAD) trial. "Our study demonstrates that, in general, results are timely and that antiretroviral prophylaxis can be provided promptly to HIV-infected women and their infants," Marc Bulterys, MD/PhD, CDC, et al., explain in the July 14 issue of JAMA. Rapid HIV-1 tests administered during labor were 100% sensitive and 99.9% specific with a positive predictive value of 90%. Perinatal HIV testing would be especially valuable in the developing world, where "pregnant women with unknown HIV status are often seen by clinicians for the first time during labor," the authors note...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT020584

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel